Cancer R&D 2024 has wrapped up successfully. We’re grateful for your interest and interaction with Alfa Cytology. We’re eager to continue providing our expertise in cancer drug development. Let’s look back on these memorable moments!

Learn More
Banner

Adenosquamous Carcinoma

Adenosquamous Carcinoma

Alfa Cytology provides specialized services tailored to the intricate demands of adenosquamous carcinoma research, a distinct and aggressive variant of pancreatic cancer. Leveraging cutting-edge technology and deep expertise, we aim to advance the understanding of adenosquamous carcinoma pathogenesis, identify novel therapeutic targets, and support the preclinical development of innovative treatments.

Introduction to Adenosquamous Carcinoma

Adenosquamous carcinoma is a rare and aggressive subtype of pancreatic cancer characterized by the presence of both glandular (adenocarcinoma) and squamous cell carcinoma components. It primarily affects organs such as the lungs, pancreas, cervix, and esophagus. Adenosquamous carcinoma constitutes approximately 1-4% of all pancreatic cancer cases and is associated with a poorer prognosis compared to pancreatic adenocarcinoma. This carcinoma exhibits unique histopathological features, including the coexistence of two distinct cell types, which complicates its diagnosis and treatment.

Fig. 1 Squamous cell carcinoma and adenosquamous cell carcinoma formation.Fig. 1 Squamous cell carcinoma and adenosquamous cell carcinoma formation. (Zhang, W.; et al., 2023)

Therapeutics for Adenosquamous Carcinoma

The development of targeted therapies for adenosquamous carcinoma is a promising and rapidly evolving area of research. Several drugs are currently in various stages of the developmental pipeline, and here are some key examples.

Therapeutics Molecular Type Target Phase
AMG 510 Small Molecule Inhibitor KRAS G12C Phase II
Pembrolizumab Monoclonal Antibody PD-1 Phase III
Olaparib Small Molecule Inhibitor PARP Phase III
Durvalumab Monoclonal Antibody PD-L1 Phase III
Ipilimumab Monoclonal Antibody CTLA-4 Phase II
Tislelizumab Monoclonal Antibody PD-1 Phase III
Lenvatinib Multi-kinase Inhibitor VEGFR, FGFR, PDGFR, RET, KIT Phase III
Bempegaldesleukin Pathway Agonist IL-2 receptor Phase III
Evorpacept Small Molecule Inhibitor CD47 Phase II

Our Services

Alfa Cytology offers a comprehensive suite of research services, including basic research, in vitro and in vivo modeling, molecular characterization, drug screening, and therapeutic efficacy testing, etc. Our main goal is to promote groundbreaking research for new therapeutic approaches, contributing to the broader effort of combating pancreatic cancer.

Basic Research Services for Adenosquamous Carcinoma

Alfa Cytology provides robust therapeutic development services aimed at advancing treatments for adenosquamous carcinoma. These services encompass the entire drug development pipeline from initial screening to preclinical testing.

Adenosquamous Carcinoma Biology Research Services

  • Cancer Cell-based Assay
  • Cell Signaling Pathway Analysis
  • Single Cell ICP-MS

Molecular Biology Services

  • Analysis of Gene Mutations in Tumors
  • Molecular Characterization of Tumor Metastasis
  • Analysis of Epigenetic Regulation in Tumors
  • Identification of Molecular Subtypes in Tumors
  • Analysis of Non-coding RNA-mediated Regulation in Tumors

Progression and Metabolic Analysis

  • Tumorigenesis and Metastasis Analysis
  • Cancer Metabolism Analysis

Therapeutic Development Services

Alfa Cytology provides robust therapeutic development services aimed at advancing treatments for adenosquamous carcinoma. These services encompass the entire drug development pipeline from initial screening to preclinical testing.

Small Molecule Drug Development

Identification and optimization of small molecules targeting key pathways and genetic mutations involved in adenosquamous carcinoma.

Immunotherapy

Design and testing of immune checkpoint inhibitors, cancer vaccines, and adoptive cell therapies to enhance the immune response against adenosquamous carcinoma.

Gene Therapy

Exploration of gene-editing technologies, such as CRISPR/Cas9, to correct genetic defects and inhibit tumor growth.

Biologic Therapeutics

Development of monoclonal antibodies, vaccines, and other biologics targeting specific antigens and signaling pathways.

Preclinical Research Services

By employing different study models and techniques, Alfa Cytology can comprehensively evaluate the safety, efficacy and pharmacokinetic properties of anti-adenosquamous carcinoma drugs, laying a solid foundation for subsequent trials.

Efficacy Evaluation for Drugs

  • In Vitro Efficacy Evaluation
  • In Vivo Efficacy Evaluation

Safety Assessment for Drugs

  • Toxicology Evaluation
  • Immunogenicity and Immunotoxicity Evaluation

Alfa Cytology is dedicated to advancing the field of pancreatic cancer research through our specialized preclinical services. Our comprehensive offerings, including therapeutic development, cancer modeling, and analytical services, are tailored to meet the unique challenges of adenosquamous carcinoma. The types of molecules we can develop involve small-molecule drugs, therapeutic antibodies, peptide drugs, gene therapies, cellular therapies, and more. For more information on our services and how we can support your research endeavors, please contact us.

Reference

  1. Zhang W, et al. Research advances and treatment perspectives of pancreatic adenosquamous carcinoma. Cell Oncol (Dordr). 2023, 46(1):1-15.
All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.